Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study by Evans, T, Wylie, E, Garcia, J, Coxon, F, Wall, L, Eatock, M, Maughan, T, Highley, M, Zimmerli, P

The pharmacology of bisphosphonates and new insights into their mechanisms of action. by Russell, R, Rogers, M, Frith, J, Luckman, S, Coxon, F, Benford, H, Croucher, P, Shipman, C, Fleisch, H

Differential effects of alpha-halogenation on the potency of bisphosphonates and phosphonocarboxylates for inhibition of their target enzymes by Stewart, C, Dunford, J, Xia, Z, Baron, R, Marma, MS, Kashemirov, B, McKenna, C, Ebetino, F, Coxon, F

Role of the geminal hydroxyl group in target enzyme inhibition by bisphosphonates and phosphonocarboxylates by Stewart, C, Dunford, J, Xia, Z, Baron, R, Marma, MS, Kashemirov, B, McKenna, C, Ebetino, F, Coxon, F

Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer by Douillard, J, Twelves, C, McKendrick, J, Bertetto, O, Coxon, F, Diaz-Rubio, E, Dufour, P, Maughan, T, Scheithauer, W, Burris, H

Fluorescently labeled risedronate and related analogues: "magic linker" synthesis. by Kashemirov, B, Bala, J, Chen, X, Ebetino, F, Xia, Z, Russell, R, Coxon, F, Roelofs, A, Rogers, M, McKenna, C

Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). by Diaz-Rubio, E, Burris, H, Douillard, J, Coxon, F, Maughan, T, Bertetto, O, Schueller, J, Husseini, F, Marschner, N, Scheithauer, W, Grp, X

Bone mineral affinity influences the distribution of a bisphosphonate and a lower affinity analogue in vivo by Roelofs, A, Boyde, A, Lundy, M, McKenna, C, Blazewska, K, Sun, S, Kashemirov, B, Russell, R, Ebetino, F, Rogers, M, Coxon, F

Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. by Roelofs, A, Stewart, C, Sun, S, Błażewska, K, Kashemirov, B, McKenna, C, Russell, R, Rogers, M, Lundy, M, Ebetino, F, Coxon, F

Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. by Marma, MS, Xia, Z, Stewart, C, Coxon, F, Dunford, J, Baron, R, Kashemirov, B, Ebetino, F, Triffitt, J, Russell, R, McKenna, C

Fluorescently labeled risedronate and related analogs: Design and evaluation as imaging probes by Coxon, F, Bala, J, Kashemirov, B, Lundy, M, Chen, X, Xia, Z, Dunford, J, Russell, G, Roelofs, A, Rogers, M, McKenna, C, Ebetino, F

Fluorescently labeled risedronate and related analocs: Design and evaluation as imaging probes by Coxon, F, Bala, J, Kashemirov, B, Roelofs, A, Lundy, M, Chen, X, Xia, Z, Dunford, J, Russell, R, Rogers, M, McKenna, C, Ebetino, F

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. by Russell, R, Xia, Z, Dunford, J, Oppermann, U, Kwaasi, A, Hulley, P, Kavanagh, K, Triffitt, J, Lundy, M, Phipps, R, Barnett, B, Coxon, F, Rogers, M, Watts, N, Ebetino, F

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. by Russell, R, Xia, Z, Dunford, J, Oppermann, U, Kwaasi, A, Hulley, P, Kavanagh, K, Triffitt, J, Lundy, M, Phipps, R, Barnett, B, Coxon, F, Rogers, M, Watts, N, Ebetino, F

Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]py... by McKenna, C, Kashemirov, B, Błazewska, K, Mallard-Favier, I, Stewart, C, Rojas, J, Lundy, M, Ebetino, F, Baron, R, Dunford, J, Kirsten, M, Seabra, M, Bala, J, Marma, MS, Rogers, M, Coxon, F

Periampullary Cancer ESPAC-3(v2) trial: a Randomised Controlled Phase III Trial of Adjuvant Chemotherapy Versus Observation in Patients With Periampullary Adenocarcinomas of the He... by Neoptolemos, J, Moore, M, Cox, T, Valle, J, Palmer, D, Mcdonald, A, Carter, R, Tebbutt, N, Dervenis, C, Smith, D, Glimelius, B, Coxon, F, Lacaine, F, Middleton, M, Ghaneh, P, Bassi, C, Halloran, C, Olah, A, Rawcliffe, C, Buechler, M

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. by Cassidy, J, Douillard, J, Twelves, C, McKendrick, J, Scheithauer, W, Bustová, I, Johnston, P, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K, Cowell, W, Garrison, L